Digital PCR Markets 2027–2031

Digital PCR Markets: Market Forecast, Competitive Landscape, Technology and World Metropolitan Area Market Sizes, 2027–2031

Global forecasts of digital PCR supplier revenue by partitioning technology, product, application, end user and regulatory status, for 14 countries and regions and 237 metropolitan areas, with 36 company profiles. Droplet, nanoplate and chip-based systems, consumables, assays and software for research, biopharma QC, oncology, transplant, infectious disease and wastewater testing.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Digital PCR counts molecules instead of estimating them, and that precision is taking the technology out of the research laboratory and into regulated work: release testing for cell and gene therapies, molecular residual disease, transplant monitoring and cleared diagnostic tests. Competition is moving from partition counts to workflow, validated assay menus and regulatory status. The market grows from $700.0 million in 2026 to $1,179.5 million in 2031, at 11.0% a year, and by 2031 regulated uses make up 48.0% of it.

Market Size 2026: USD $700.0M Market Size 2031: USD $1,179.5M CAGR: 11.0%

Situation Analysis: what is really happening

• Research slows. Life Science Research is still the largest application at 33.0% of the market, but grows only 7.0% a year as academic funding weakens, falling to 27.5% by 2031.
• Biopharma QC and oncology lead. Cell & Gene Therapy & Biopharma QC grows 15.1% a year and Oncology & Liquid Biopsy 13.9%; together they add 59% of all growth.
• From research use only to GMP and IVD. Cleared/Certified IVD products grow 19.5% a year and GMP & Biopharma QC 16.7%, while Research Use Only falls from 62.0% to 52.0% of the market.
• Kits pull through. Assays & Kits are the fastest-growing product line at 16.1% a year, while Instruments grow 7.4% as the installed base matures.
• New formats gain. Chip & Other systems grow 20.0% a year, from 10.5% to 15.5% of the market, and Nanoplate & Microchamber Arrays rise from 33.5% to 37.0%.
• New owners. Bio-Rad completed its acquisition of Stilla Technologies, Roche acquired SAGA Diagnostics, ARCHIMED completed its purchase of Biomark, and QIAGEN agreed to be taken private by EQT. China is the second-largest country market, at $91.2 million in 2026.

Company Analysis: who is positioned, who is exposed

• Bio-Rad Laboratories, QIAGEN, Thermo Fisher Scientific and Roche Diagnostics: The global platform makers, with HSR’s estimates of each company’s digital PCR revenue and ranges.
• Beijing TargetingOne, Pilot Gene Technologies, Sinafu, RainSure Scientific and Maccura Biotechnology: China’s digital PCR makers.
• Biomark Scientific, Countable Labs, Sysmex, BioTNS, Optolane Technologies, Bioneer, JN Medsys and PreciGenome: Other platform makers and emerging technologies.
• Integrated DNA Technologies, LGC Biosearch Technologies, Horizon Discovery (Revvity), EntroGen, Gencurix, GT Molecular, Pxlence, ChromaCode and Hamilton Company: Assays, reference materials, kits and automation.
• Foundation Medicine’s SAGA Diagnostics, iMDx, Naveris (CareDx), Biodesix and Geneoscopy: Clinical test developers using digital PCR.
• Charles River Laboratories, Eurofins BioPharma Product Testing, CellCarta, GC Labs and WastewaterSCAN: Testing laboratories and public health programmes.

In all, 36 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Inside the report: HSR’s revenue estimate for every named company, with low–high ranges, and a growth and share-change map of every application and technology line. Names and values are in the full report.

Questions this report answers

• How large is the digital PCR market, and how fast will it grow?
• How much digital PCR revenue do Bio-Rad, QIAGEN, Thermo Fisher, Roche and China’s suppliers earn?
• How fast are biopharma QC, oncology and transplant testing taking share from research?
• Which partitioning technologies and product lines win as competition moves to workflow and regulatory status?
• What do IVDR, FDA clearances, NMPA approvals and GMP requirements mean for suppliers?
• How large is each country market, and which metropolitan areas lead?

What's inside

• 382 pages, 23 chapters, 130 tables and 58 figures
• Forecasts for 2027–2031 from a 2026 base year, by partitioning technology, product, application, end user and regulatory status, for 14 countries and regions
• Market sizes for 237 world metropolitan areas in 2026 and 2031, with the top 30 and fastest-growing metros
• How digital PCR works; partitioning technologies, products, applications and end users; technology trends; IVD – The Big Picture
• Regulation and quality; 10 market-moving developments; competitive landscape with company revenue estimates, SWOT, Porter's Five Forces and strategic recommendations
• 36 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Instrument and assay suppliers: size target segments by application, end user and regulatory status, and benchmark competitors.
• Biopharma and CDMOs: understand the tools for GMP release testing of cell and gene therapies.
• Clinical laboratories and test developers: plan MRD, liquid biopsy and transplant testing.
• Investors: assess consolidation, take-privates and growth.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.